In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amazon Supplements, OTC Drugs Ride Lower Prices To Gains In Market Share

Executive Summary

Amazon’s Solimo supplement and Basic Care OTC lines unlikely to expand much, says Jefferies analyst Brian Tanquilut. Still, brands are well positioned against retail private label competitors, as most products are priced lower than similar products by Walgreens and CVS.

You may also be interested in...



Amazon Among Retailers Slashing Prices On Supplements, Personal Care Over ‘Cyber 5’ Stretch

Amazon will offer savings of 25% on own-brand Solimo purchases starting the weekend of Cyber Monday, among other promotions planned across its dietary supplement and personal-care categories. Meanwhile, Vitamin Shoppe and GNC will be discounting products up to 40% during the typically busy five-day stretch for nutrition and wellness shopping.

Amazon Expands Consumer Health With Advantage Of Cutting Prices

E-commerce giant expands consumer health footprint in past six months with launches of generic OTC drug product lines at prices in some cases significantly undercutting competitors.  Primary Health and SoundHealth OTC drugs range from a few dollars less to about half the cost of brand name equivalents.

Amazon's Solimo Supplements' Prices, Selection Slow Market Share Incursion

Amazon’s Solimo supplements and personal care line overall is priced higher than Walgreens' brand but lower than CVS', Jefferies Equity Research Americas found. Solimo could present a formidable threat to the supplements category, but its limited assortment so far and pricing should prevent “material market share shifts” in the near-term, Jefferies says.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

AG032815

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel